Ginsenosides Rk1 and Rg5 Inhibit Transforming Growth Factor-β1-induced Epithelial-mesenchymal Transition and Suppress Migration, Invasion, Anoikis Resistance, and Development of Stem-like Features in Lung Cancer
Overview
Authors
Affiliations
Background: Lung cancer has a high incidence worldwide, and most lung cancer-associated deaths are attributable to cancer metastasis. Although several medicinal properties of Meyer have been reported, the effect of ginsenosides Rk1 and Rg5 on epithelial-mesenchymal transition (EMT) stimulated by transforming growth factor beta 1 (TGF- β1) and self-renewal in A549 cells is relatively unknown.
Methods: We treated TGF-β1 or alternatively Rk1 and Rg5 in A549 cells. We used western blot analysis, real-time polymerase chain reaction (qPCR), wound healing assay, Matrigel invasion assay, and anoikis assays to determine the effect of Rk1 and Rg5 on TGF-mediated EMT in lung cancer cell. In addition, we performed tumorsphere formation assays and real-time PCR to evaluate the stem-like properties.
Results: EMT is induced by TGF-β1 in A549 cells causing the development of cancer stem-like features. Expression of E-cadherin, an epithelial marker, decreased and an increase in vimentin expression was noted. Cell mobility, invasiveness, and anoikis resistance were enhanced with TGF-β1 treatment. In addition, the expression of stem cell markers, CD44, and CD133, was also increased. Treatment with Rk1 and Rg5 suppressed EMT by TGF-β1 and the development of stemness in a dose-dependent manner. Additionally, Rk1 and Rg5 markedly suppressed TGF-β1-induced metalloproteinase-2/9 (MMP2/9) activity, and activation of Smad2/3 and nuclear factor kappa B/extra-cellular signal regulated kinases (NF-kB/ERK) pathways in lung cancer cells.
Conclusions: Rk1 and Rg5 regulate the EMT inducing TGF-β1 by suppressing the Smad and NF-κB/ERK pathways (non-Smad pathway).
He C, He J Mol Cell Biochem. 2025; .
PMID: 39821582 DOI: 10.1007/s11010-024-05199-3.
Xu R, Du A, Li J, Yang Q Am J Cancer Res. 2024; 14(11):5116-5132.
PMID: 39659934 PMC: 11626272. DOI: 10.62347/MJTA2660.
Chen Y, Luo W, Hu M, Yao X, Wang J, Huang Y Oncol Lett. 2024; 29(1):62.
PMID: 39611065 PMC: 11602830. DOI: 10.3892/ol.2024.14808.
Fang X, Wei M, Liu X, Lu L, Liu G Transl Cancer Res. 2024; 13(10):5458-5472.
PMID: 39525036 PMC: 11543027. DOI: 10.21037/tcr-24-264.
Effect of ginseng and ginsenosides on attention deficit hyperactivity disorder: A systematic review.
Kim Y, Cho I, Cho S J Ginseng Res. 2024; 48(5):437-448.
PMID: 39263306 PMC: 11385392. DOI: 10.1016/j.jgr.2024.05.006.